Results 231 to 240 of about 158,321 (287)

Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B‐cell lymphoma

open access: yesBritish Journal of Haematology, EarlyView.
This study examined the effect of MYD88L265P (myeloid differentiation primary response gene 88 mutation L265P) and/or CD79BY196 (cluster of differentiation 79B gene mutation Y196) on central nervous system (CNS) relapse in 270 patients with newly diagnosed diffuse large B‐cell lymphoma.
Tomotaka Suzuki   +14 more
wiley   +1 more source

Adrenal gland haemangioma, a rare entity difficult to differentiate from malignancy. [PDF]

open access: yesBJR Case Rep
López Gómez P   +3 more
europepmc   +1 more source

Validation of target‐enriched enzymatic methylation sequencing for brain tumor classification from formalin‐fixed paraffin embedded‐derived DNA

open access: yesBrain Pathology, EarlyView.
Target‐enriched enzymatic methylation sequencing (TEEM‐seq), a DNA methylation sequencing method using the Twist Human Methylome panel, shows comparable performance to array‐based tumor methylation profiling. The method is compatible with both frozen and formalin‐fixed paraffin‐embedded (FFPE) samples and is a viable approach to tumor methylation and ...
Quynh T. Tran   +6 more
wiley   +1 more source

Pseudocysts of the Adrenal Gland: A Systematic Review of Existing Scientific Literature From 2000 to 2023. [PDF]

open access: yesCureus
Dar SA   +8 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy